Hello again Snupoled,
I am for the most part sober this Sunday afternoon and chastising myself for my DD laziness and naivete. The revelation that Armen controls RXMD outright was a surprise. FaceBook being a notable exception, control of a corp. by a single individual isn't an issue for companies I look at, so I didn't check that with RXMD.
It puts a disturbing perspective on RXMD's decision to renew Midam's contract after the first expired with no results. I'm not suggesting anything underhanded, but it strikes me as evidence of inept use of funds without oversight. Armen's background is well known and does not inspire confidence in his competency to safeguard RXMD shareholder interests.
Obviously, that makes RXMD a poor candidate for a hostile takeover. An acquiring company would first have to pay Armen however much he asked for his 51 Series A stocks.
The disconnect between RXMD's performance and share price has not been credibly explained by any posters on this board. MM manipulation? They make money on the spread, not the price level.
Dilution is not an issue as far as I can see. (But then I'm proven to be lazy.)
The bilateral trading gambit, as has been mentioned by some posters, seems the most reasonable technically, but it isn't that hard for SEC to spot. Of course, SEC is understaffed, so why not take the chance?
Anyway, the discrepancy between price and performance continues to confound me.
On the operations side, as you have many times pointed out, things look grand.
Using DPLO as an example, we see a PSR of 2 as a reasonable price target for RXMD. That would make it undervalued by a factor of about 4, head guess from my last calculation. PSR 2 is conservative for the sector as a whole.
Getting there requires a published audit and an "uplist" to QB or higher. That does not mean audit and uplist will necessarily result in a price rise, only that they are necessary. To repeat an earlier post, a specific move to boost share price in conjunction with an uplist should do wonders.
An audit could be published in February, if not, then March as per RXMD's stated goal. QB uplist would then be possible in 2Q after SEC filing and fee payment. In that scenario, I expect some gains in the next one or two months and approaching double digits in 2Q earliest and 3Q latest.
If RXMD management does something specifically designed to boost share price, then fair value (at least PSR 2) by 2Q-3Q.
Exponential growth beyond getting to current fair value will depend on M&A. Any merger or acquisition, as I belatedly understand, will be made for the express personal benefit of Armen. (Unless he is an altruistic individual, which I doubt. He has absolute control of the company.) Any benefits accruing to common shareholders will be happenstance.
As (or if) the share price approaches fair value, holders of zillions of shares are likely to start selling. The trick is to bring in enough new investors to counter the selling, thus making fair value an ever elusive target.
The floor is now open to non sequitur brickbats from Kelly Ann Conway wanna be's.
p.s. Anyone who has anything to say about the improper use of "uplist" can only have the mentality of a pedantic schoolmarm. Guilty, I still grit my teeth when I see "reiterate." "Iterate" means repeat. Why the "re." "Comprised of" arghhh!
p.p.s. Hang onto your shares lads and lasses. A triple should be in the works for 2017 1H assuming things aren't continually screwed up by whoever's been working the SP so far.
